Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Details : Stride's Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Truvada Tablets, 200 mg/300 mg, of Gilead Sciences.
Product Name : Truvada-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data showed that ATI-2173 alone, or in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated among the cohorts, and ATI-2173 and TDF suppressed HBV DNA and induced declines in biomarkers of cccDNA activity.
Product Name : ATI-2173
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2022
Lead Product(s) : ATI-2173,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cabotegravir,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NDA was based on the results from two phase IIb/III studies, HPTN 083 and HPTN 084, which evaluated the safety and efficacy of cabotegravir long-acting for PrEP in men who have sex with men, transgender women, and cisgender women use in HIV preventio...
Product Name : Cabenuva
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Cabotegravir,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Details : Lupin has received approval from the United States Food and Drug Administration (USFDA) to market its Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 200 mg/300 mg. The drugs are indicated in combination with other antiretroviral agents for HIV-...
Product Name : Descovy-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF).
Product Name : Truvada
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2020
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® and ATRIPLA® Tablets in the U.S.
Details : Emtricitabine and Tenofovir Disoproxil Fumarate Tablets and Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are both combination treatments available as a single pill with similar safety profiles to their reference products.
Product Name : Truvada-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2020
Lead Product(s) : Emtricitabine,Tenofovir Disoproxil Fumarate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
